🔬Deep Research

AHCO — AdaptHealth Corp · catalysts, narrative & risks

·17 sourcesAHCO forecast →

AdaptHealth Corp. (NASDAQ: AHCO) — Research Snapshot as of October 27, 2026

Recent Catalysts (approximately July–October 2026)

Q2 2026 earnings blowout and guidance cut (August 4, 2026). This is the dominant catalyst. AdaptHealth reported an EPS of -$0.99, missing consensus of roughly +$0.17 by about $1.16, and reported revenue of $740.31 million [1][6][7]. It then issued sharply downward guidance, cutting full-year sales guidance from ~$3.45–3.52 billion to ~$2.85–2.89 billion, adjusted EBITDA guidance from ~$680–730 million to ~$490–520 million, and free cash flow guidance from ~$175–225 million to ~$80–120 million [1]. Management attributed part of the revision to excluding the discontinued Diabetes Health business [1][15].


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →